Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins
Langmuir · 2023
DOI: 10.1021/acs.langmuir.3c01173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Langmuir, 2023. Verfasst von Jacob K Al-Husseini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Children's Hospital Los Angeles, Los Angeles, California 90027, United States. Hauptthemen laut MEDLINE: beta-Cyclodextrins, Cyclodextrins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Alternatives Research and Development Foundation, Pomona College, Arnold and Mabel Beckman Foundation.
Abstract (Originalsprache)
Despite advancements in contemporary therapies, cardiovascular disease from atherosclerosis remains a leading cause of mortality worldwide. Supported lipid bilayers (SLBs) are membrane interfaces that can be constructed with varying lipid compositions. Herein, we use a solvent-assisted lipid bilayer (SALB) construction method to build SLB membranes with varying cholesterol compositions to create a lipid-sterol interface atop a piezoelectric sensor. These cholesterol-laden SLBs were utilized to investigate the mechanisms of various cholesterol-lowering drug molecules. Within a flow-cell, membranes with varying cholesterol content were exposed to cyclodextrins 2-hydroxypropyl-beta-cyclodextrin (HPβCD) and methyl-beta-cyclodextrin (MβCD). Quartz-crystal microgravimetry with dissipation monitoring (QCM-D) enabled the collection of in vitro, real-time changes in relative areal mass and dissipation. We define the cholesterol desorbing competency of a cyclodextrin species via measures of the rate of cholesterol removal, the rate of the transfer of membrane-bound cholesterol to drug-complexed cholesterol, and the binding strength of the drug to the cholesterol-ladened membrane. Desorption data revealed distinct cholesterol removal kinetics for each cyclodextrin while also supporting a model for the lipid-cholesterol-drug interface. We report that MβCD removes a quantity of cholesterol 1.61 times greater, with a speed 2.12 times greater, binding affinity to DOPC lipid interfaces 1.97 times greater, and rate of internal cholesterol transfer 3.41 times greater than HPβCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Children's Hospital Los Angeles, Los Angeles, California 90027, United States.
- The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California 90027, United States.
- Department of Chemistry, Pomona College, Claremont, California 91711, United States.
ORCID-Profile: Jacob K Al-Husseini, Malkiat S Johal
Förderung
- Alternatives Research and Development Foundation
- Pomona College
- Arnold and Mabel Beckman Foundation
- Children's Cancer Research Fund
Zitieren
APA
Al-Husseini, J. K., Fong, E. M., Wang, C., Ha, J. H., Upreti, M., Chiarelli, P. A., & Johal, M. S. (2023). Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins. Langmuir. https://doi.org/10.1021/acs.langmuir.3c01173
Vancouver
Al-Husseini JK, Fong EM, Wang C, Ha JH, Upreti M, Chiarelli PA, et al. Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins. Langmuir. 2023. doi:10.1021/acs.langmuir.3c01173
BibTeX
@article{AlHusseini2023,
author = {Al-Husseini, Jacob K and Fong, Ethan M and Wang, Chris and Ha, Joseph H and Upreti, Meenakshi and Chiarelli, Peter A and Johal, Malkiat S},
title = {Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins},
journal = {Langmuir},
year = {2023},
doi = {10.1021/acs.langmuir.3c01173}
}
EUVIMED